[1] 杨襄蓉.阿德福韦酯治疗慢性乙肝疗效欠佳联合拉米夫定和替比夫定治疗的疗效观察[J].现代中西医结合杂志,2012,21(12):1298.
[2] 马子东,冯朋,周益文,等.乙型肝炎免疫球蛋白对阻断乙型肝炎病毒母婴传播的疗效和安全性研究[J].蚌埠医学院学报,2014,39(9):1185.
[3] DIEOSTAG JL,SCHIFF ER,WRIGHT TL,et al.Lamivudine as initial treatment for chronic hepatitis B in the United States[J].N Engl J Med,1999,341(17):1256.
[4] 权耀生.替比夫定联合阿德福韦酯治疗HBeAg阳性慢性乙型肝炎疗效观察[J].中国医药指南,2011,9(36):134.
[5] LAI CL,DIENSTAG J,SCHIFF E,et al.Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B[J].Clin Infect Dis,2003,36(6):687.
[6] LOCARNINI S,MASON WS.Cellular and virological mechanisms of HBV drug resistance[J].J Hepatol,2006,44(2):422.
[7] 宋立文,赵桂鸣,曹武奎,等.比较替比夫定与拉米夫定治疗慢性乙型肝炎疗效的Meta分析[J].临床肝胆病杂志,2011,27(9):955.
[8] LAI CL,LEUNG N,TEO EK,et al.A 1-year trial of telbivudine,lamivudine,and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B[J].Gastroenterology,2005,129(2):528.
[9] 贾继东,侯金林,尹有宽,等.替比夫定或拉米夫定抗乙型肝炎病毒的疗效预测探讨[J].中华肝脏病杂志,2007,15(3):342.
[10] 李蔚莉,马秀云,吴璐,等.替比夫定与拉米夫定长期治疗慢性乙型肝炎患者疗效与安全性的随机对照研究[J].药物不良反应杂志,2010,12(2):77.
[11] 金清龙,王中峰,闫红青,等.替比夫定和拉米夫定治疗慢性乙型肝炎对肌酸激酶的影响[J].临床肝胆病杂志,2011,27(2):143.